Bal Pharma Board of Directors

Get the latest insights into the leadership at Bal Pharma. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Shailesh SiroyaManaging Director
Himesh VirupakshayaWhole Time Director
Nicola NeeladriNon Executive Independent Director
Jatish ShethNon Executive Independent Director
HS VenkateshNon Executive Independent Director
Ravindra Kumar KothariNon Executive Director
Abdul BasithCompany Secretary & Compliance Officer
Bheekamchand MukeshNon Executive Independent Director

Bal Pharma Share price

BALPHARMA

77.02

1.16 (-1.48%)
NSE
BSE
Last updated on 23 Apr, 2026 | 11:59 IST
Today's High

78.77

Today's Low

76.61

52 Week Low

60.00

52 Week High

117.28

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Bal Pharma FAQs

The board at Bal Pharma consists of experienced professionals, including Shailesh Siroya, Himesh Virupakshaya, and others, overseeing the company’s strategic and corporate governance.

Directors at Bal Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Shailesh Siroya is the current chairman at Bal Pharma.

Executive directors at Bal Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Bal Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Bal Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost